Fig. 1

Prediction of DIPG drug hits. A Working model. In vitro/in vivo illustrations were taken from Biorender. B DIPG samples in a tumor map comprising > 17,000 samples. The tumor map is a t-distributed stochastic neighbor embedding (t-SNE) plot of sample TPM expressions. DIPG and brain cancer samples are highlighted. C Correlation between predicted reversal gene expression scores (sRGES) and experimental drug efficacy with a half maximal activity concentration (AC50) value. A lower sRGES means a higher potency to reverse the DIPG signature genes. The drug corresponding to the dot plot are described in Additional file 1: Table S1). D Meta-disease genes and their enriched pathways. The pathways commonly changed by the predicted drugs are highlighted. E Enriched target class of CDK in the predictions. The black line on the left suggests it is ranked on the top in the prediction list. An enriched target class means the ligands of the target tend to be highly ranked in the predictions. The enrichment of other two targets (TOP, HDAC) are illustrated in Additional file 4: Fig. S1(three eample drugs are labeled in each plot). F Top candidates selected for validation. The first row shows the meta disease signature. The signatures of four top candidates and three randomly selected control compounds are visualized. The altered genes are listed in Additional file 6: Table S5